StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.16−0.04 (-1.82%)

Close on Nov 17, 2026Market cap $103.14MP/E –Yield –

Minerva Neurosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Minerva Neurosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$26.17M. For fiscal 2025 it was -$13.51M. The highest annual figure on record is $3.09M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.51M–
FY2024Dec 31, 2024-$19.55M–
FY2023Dec 31, 2023-$14.78M–
FY2022Dec 31, 2022-$24.65M–
FY2021Dec 31, 2021-$24.60M–
FY2020Dec 31, 2020-$33.82M–
FY2019Dec 31, 2019-$43.43M–
FY2018Dec 31, 2018-$41.94M-1456.1%
FY2017Dec 31, 2017$3.09M–
FY2016Dec 31, 2016-$25.69M–
FY2015Dec 31, 2015-$24.27M–
FY2014Dec 31, 2014-$35.96M–
FY2013Dec 31, 2013-$2.16M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$13.34M–
Q1 FY2026Mar 31, 2026-$5.43M–
Q4 FY2025Dec 31, 2025-$4.48M–
Q3 FY2025Sep 30, 2025-$2.92M–
Q2 FY2025Jun 30, 2025-$2.04M–
Q1 FY2025Mar 31, 2025-$4.07M–
Q4 FY2024Dec 31, 2024-$5.17M–
Q3 FY2024Sep 30, 2024-$4.35M–
Q2 FY2024Jun 30, 2024-$3.94M–
Q1 FY2024Mar 31, 2024-$6.09M–
Q4 FY2023Dec 31, 2023-$5.99M–
Q3 FY2023Sep 30, 2023-$4.81M–
Q2 FY2023Jun 30, 2023-$3.87M–
Q1 FY2023Mar 31, 2023-$115.41K–
Q4 FY2022Dec 31, 2022-$4.11M–
Q3 FY2022Sep 30, 2022-$9.53M–
Q2 FY2022Jun 30, 2022-$5.19M–
Q1 FY2022Mar 31, 2022-$5.81M–
Q4 FY2021Dec 31, 2021-$4.83M–
Q3 FY2021Sep 30, 2021-$8.63M–
Q2 FY2021Jun 30, 2021-$5.92M–
Q1 FY2021Mar 31, 2021-$5.22M–
Q4 FY2020Dec 31, 2020-$7.16M–
Q3 FY2020Sep 30, 2020-$9.87M–
Q2 FY2020Jun 30, 2020-$7.59M–
Q1 FY2020Mar 31, 2020-$9.20M–
Q4 FY2019Dec 31, 2019-$14.18M–
Q3 FY2019Sep 30, 2019-$9.52M–
Q2 FY2019Jun 30, 2019-$10.13M–
Q1 FY2019Mar 31, 2019-$9.60M–
Q4 FY2018Dec 31, 2018-$9.80M–
Q3 FY2018Sep 30, 2018-$9.98M-140.1%
Q2 FY2018Jun 30, 2018-$11.23M–
Q1 FY2018Mar 31, 2018-$10.93M–
Q4 FY2017Dec 31, 2017-$8.91M–
Q3 FY2017Sep 30, 2017$24.89M–
Q2 FY2017Jun 30, 2017-$6.84M–
Q1 FY2017Mar 31, 2017-$6.04M–
Q4 FY2016Dec 31, 2016-$8.93M–
Q3 FY2016Sep 30, 2016-$4.66M–

More Minerva Neurosciences figures

See a number that looks wrong?